Rapport Therapeutics (RAPP) Stock: Buy, Sell, or Hold?
RAPP - Rapport Therapeutics, Inc. Common Stock
$43.62
0.16 (0.37%)
▲
5d:
-8.46%
30d:
-8.61%
90d:
+23.89%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 05, 2026
Get Alerted When RAPP Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: RAPP shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: RAPP shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: RAPP is currently trading at $43.62, which is considered oversold relative to its 30-day fair value range of $45.23 to $49.90.
Technical Outlook: Technically, RAPP is in a strong uptrend. The price is currently testing key support at $42.65. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: RAPP scores 28/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $62.05 (+42.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, RAPP is in a strong uptrend. The price is currently testing key support at $42.65. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: RAPP scores 28/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $62.05 (+42.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$45.23 -
$49.90
Company Quality Score
47/100
(HOLD)
Options IV Signal
48th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
60.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Options fairly priced (IV 48th percentile)
- BEARISH: Weak technical setup (28/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 42.2% below Wall St target ($62.05)
- WARNING: Composite score 47/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$45.23 -
$49.90
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$7.17
(16.4%)
Support & Resistance Levels
Support Level
$42.65
Resistance Level
$50.68
Current Trend
Strong Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-8.34
Wall Street Target
$62.05
(+42.2%)
Share & Embed Analysis
Last updated: September 13, 2026 11:50 AM ET
Data refreshes hourly during market hours. Next update: 12:50 PM
Data refreshes hourly during market hours. Next update: 12:50 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RAPP showing a specific setup today?
Insider Activity (6 Months)
0
Buys
6
Sells
Net
INSIDERS SELLING
Recent Transactions
Rock Ventures V L.P. Thi…
SELL
426005 shares
2026-04-17
Krishnaswamy Yeleswaram
SELL
20225 shares
2026-04-17
Krishnaswamy Yeleswaram
SELL
10200 shares
2026-04-14
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$371 | 43 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$432 | 48 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$569 | 38 SELL |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$314 | 47 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 50 HOLD |